Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Texas Instruments (TXN) Reiterated at Neutral by Cantor Fitzgerald: Story as Expected
-
Workday (WDAY) Reiterates at Overweight by Cantor Fitzgerald: Q4 Not Bullet Proof
-
Supernus Pharmaceuticals (SUPN) Reiterated at Overweight Rating by Cantor Fitzgerald
-
GoDaddy (GDDY) PT Lowered to $90 at Cantor Fitzgerald: Guide implies Deceleration
-
MercadoLibre (MELI) PT Lowered to $2,400 at Cantor Fitzgerald: Outlook Unchanged
-
Cytokinetics (CYTK) Reiterated at Overweight by Cantor Fitzgerald: Encouraging Signs
-
Lucid Group (LCID) PT Lowered to $14 at Cantor Fitzgerald: Guide Disappointing
-
Zura Bio prices $125 million public offering at $6.25 per share
-
Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants
-
Bicara Therapeutics prices $150 million stock offering at $16 per share
-
Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants
-
MOZAYYX prices $261 million IPO at $10 per unit on NYSE
-
MOZAYYX Acquisition Corp. Announces the Pricing of Upsized $261,000,000 Initial Public Offering
-
Eloro Resources Announces Bought Deal LIFE Private Placement for Gross Proceeds of C$10.0 Million
-
Palvella Therapeutics launches $150 million stock offering
-
Palvella Therapeutics Announces Proposed Public Offering
-
Zura Bio announces public offering of shares and pre-funded warrants
-
Bicara Therapeutics launches $150 million public stock offering
-
Bicara Therapeutics Announces Proposed Public Offering of Common Stock
-
Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants
-
Kratos Defense & Security (KTOS) Stock: Investors Should Be More Constructive, Says Analyst
-
Cantor Fitzgerald Reiterates Neutral Rating on Primoris Services Corporation (PRIM)
-
Nuscale Power (SMR) PT Lowered to $20 at Cantor Fitzgerald on Near-Term Headwinds
-
CrowdStrike Holdings (CRWD) PT Lowered to $520 at Cantor Fitzgerald Ahead of Q4 Earnings
-
Zscaler (ZS) PT Lowered to $300 at Cantor Fitzgerald to Reflect Software Multiple Compression
-
Broadstone Net Lease (BNL) PT Raised to $21 at Cantor Fitzgerald
-
Bitcoin Standard Treasury names Bob Stefanowski as CFO
-
Bitcoin Standard Treasury Company Names Bob Stefanowski as Chief Financial Officer
-
PlusAI to Participate in Upcoming Investor Conferences
-
Remitly Global Inc (RELY) PT Raised to $20 at Cantor Fitzgerald on Q1/FY26 Guidance
-
Global Payments (GPN) PT Raised to $88 at Cantor Fitzgerald, Neutral Rating Maintained
-
Cantor Fitzgerald Reiterates Overweight Rating on NVIDIA (NVDA), Expects Beat and Raise Quarter
-
Texas Instruments (TXN) PT Raised to $250 at Cantor Fitzgerald on FCF Expectations
-
Snowflake Inc. (SNOW) PT Lowered to $250 at Cantor Fitzgerald Ahead of Earnings
-
eToro Group (ETOR) PT Raised to $52 at Cantor Fitzgerald on Improved Earnings Expectations
-
Hive Digital Technologies (HIVE) PT Lowered to $5 at Cantor Fitzgerald on Deteriorating Bitcoin Mining Economics
-
JFrog (FROG) Selloff Represents Sentiment Driven Volatility - Analyst
-
Eupraxia Pharmaceuticals raises $63.2M in public offering
-
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option
-
Cantor Fitzgerald Reiterates Overweight Rating on Materialise NV (MTLS)
-
Quanta Services (PWR) PT Raised to $630 at Cantor Fitzgerald Following Constructive Commentary
-
Cantor Fitzgerald Reiterates Overweight Rating on Onto Innovation Inc. (ONTO) Following Strong Results, Guidance
-
Cantor Fitzgerald Reiterates Overweight Rating on PTC Therapeutics (PTCT)
-
Etsy (ETSY) PT Lowered to $51 at Cantor Fitzgerald
-
Five9, Inc (FIVN) PT Lowered to $26 at Cantor Fitzgerald
-
Cantor Fitzgerald Starts Satellogic, Inc. (SATL) at Overweight
-
Candel Therapeutics prices $100 million public offering at $5.45 per share
-
Candel Therapeutics Announces Pricing of Public Offering
-
Candel Therapeutics launches $100 million public offering
-
Candel Therapeutics Announces Proposed $100 Million Public Offering

